KRAKÓW, Poland, January 25, 2018 /PRNewswire/ --
Ardigen, a leading Polish company in bioinformatics& AI for precision medicine, proves its excellence in AI by winning the 2nd place in the prestigious NCI-CPTAC DREAM-Proteogenomics Challenge. The competition gathered more than 500 participants from leading research institutions and universities
(Logo: https://mma.prnewswire.com/media/633350/Ardigen_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/633348/Ardigen_Cancer_Research.jpg )
"The NCI Proteogenomics DREAM Challenge is a world-wide collaborative effort with the final goal to provide new tools for proteogenomics data analysis and simultaneously improve our understanding of the functional relationships between DNA, RNA and proteomics data in cancer", says Francesca Petralia, Assistant Professor at Icahn School of Medicine at Mount Sinai, and co-organizer of the Challenge.
The key components of the Challenge are the novel proteogenomic data measured by the Clinical Proteomic Tumor Analysis Consortium (CPTAC). "In order to draw meaningful conclusions from such a complex dataset one needs to combine knowledge in molecular biology with that in statistical learning. The expertise in these two domains is essential for the success of the project", says Micha? Warcho?, Director of Ardigen AI Labs.
Ardigen AI Labs supports bioinformatics projects in providing state of the art AI and data science solutions. Close collaboration of data scientists with experts in cancer biology, immunology, microbiome, or central nervous system gives the synergy effect and results in competitive edge.
About Ardigen Ardigen is a leading Polish company in Bioinformatics & AI for Precision Medicine. Through proprietary know-how, experience and products Ardigen supports Life Science & Healthcare industries towards Precision Medicine. Its strength is an interdisciplinary team of world-class molecular biologists, bioinformaticians, statisticians, data scientists and software engineers who work closely together to unleash the potential of Artificial Intelligence applied to Life Sciences.
Read more about Ardigen: http://www.ardigen.com/
About the DREAM Challenge Since 2006 DREAM Challenges have been posing fundamental questions about systems biology and translational medicine. The DREAM-Proteogenomics Challenge is aimed at predicting the protein concentrations in cancer tissues using genomic and transcriptomic data. Characterization and analyses of alterations in the proteome can shed more light into cancer biology and may improve development of both biomarkers and therapeutics.
About the DREAM-Proteogenomics Challenge
Results of the DREAM-Proteogenomics Challenge
About the CPTAC
SOURCE Ardigen S.A.
Subscribe to our Free Newsletters!